Evidence map›Paper›PMID 42273359›Full record

ArticleRespirology case reports2026

Secondary Pulmonary Alveolar Proteinosis Associated With Ruxolitinib After Bone-Marrow Transplantation: A Case With Transient Improvement Following Drug Discontinuation.

Taiki Yanagi, Maki Asami-Noyama, Kaoru Yamamoto, Yoshinobu Hoshii, Yasushi Ichiyama, Masatoshi Okimura, Tetsuya Fujii, Junki Suizu, Misa Harada, Keita Murakawa and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Taiki YanagiDepartment of Respiratory Medicine National Hospital Organization Yamaguchi-Ube Medical Center Ube Yamaguchi Japan.ORCID https://orcid.org/0009-0003-6704-303X
Maki Asami-NoyamaDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan.
Kaoru YamamotoThird Department of Internal Medicine Yamaguchi University School of Medicine Ube Yamaguchi Japan.
Yoshinobu HoshiiDepartment of Diagnostic Pathology Yamaguchi University Hospital Ube Yamaguchi Japan.
Yasushi IchiyamaDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan.
Masatoshi OkimuraDepartment of Respiratory Medicine National Hospital Organization Yamaguchi-Ube Medical Center Ube Yamaguchi Japan.
Tetsuya FujiiDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan.
Junki SuizuDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan.
Misa HaradaDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan.
Keita MurakawaDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan.
Kazuki HamadaDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan.
Toshiaki UtsunomiyaYamaguchi-Ken Saiseikai Shimonoseki General Hospital Shimonoseki Yamaguchi Japan.
Yoriyuki MurataDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan.
Keiji OishiDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan.
Nobutaka EdakuniDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan.
Tomoyuki KakugawaDepartment of Pulmonology and Gerontology, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan.ORCID https://orcid.org/0000-0003-1339-1031
Tsunahiko HiranoDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan.
Kazuto MatsunagaDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine Yamaguchi University Ube Yamaguchi Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor used to treat steroid-refractory graft-versus-host disease, wherein pulmonary alveolar proteinosis (PAP) is a rare complication. We report the case of a 47-year-old woman developing respiratory failure 8 months after commencing ruxolitinib treatment. Chest computed tomography revealed bilateral ground-glass opacities. Bronchoalveolar lavage fluid was milky and periodic acid-Schiff-positive, and

Indexed as

graft‐versus‐host diseaseJanus kinase inhibitorpulmonary alveolar proteinosisruxolitinibsecondary pulmonary alveolar proteinosis

Identifiers

PMID42273359
PMCPMC13249499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.